PURPOSE: To report the 6-year biochemical disease-free outcome for hormone-naïve patients with intermediate-risk disease (Gleason score > or =7, prostate-specific antigen (PSA) > or =10 ng/ml, or clinical stage > or =T2b [1997 American Joint Committee on Cancer]) undergoing brachytherapy with supplemental external beam radiation (XRT). METHODS AND MATERIALS: Seventy-seven consecutive hormone-naïve intermediate-risk prostate cancer patients received supplemental XRT followed by a brachytherapy boost. No patient underwent pathologic lymph node staging. The median patient age was 69 years and the median follow-up was 52 months. Biochemical disease-free survival was defined by the American Society of Therapeutic Radiology and Oncology consensus definition. Clinical and treatment parameters evaluated included patient age, clinical stage, Gleason score, pretreatment PSA, and isotope. RESULTS: The 6-year actuarial biochemical no-evidence-of-disease survival rate was 97.4%. None of the evaluated clinical or treatment parameters, except for a Gleason score > or =8, predicted for failure. The mean and median posttreatment PSA was 0.08 +/- 0.19 ng/ml and <0.1 ng/ml, respectively. When stratified by isotope, the mean posttreatment PSA was not significantly different (0.07 +/- 0.11 ng/ml for 103Pd vs. 0.14 +/- 0.32 ng/ml for 125I; p=0.397). CONCLUSIONS: Hormone-naïve intermediate-risk prostate cancer patients undergoing brachytherapy with supplemental XRT have a high probability of 6-year biochemical disease-free survival. None of the evaluated clinical or treatment parameters, except Gleason score > or =8, predicted for treatment failure.
PURPOSE: To report the 6-year biochemical disease-free outcome for hormone-naïve patients with intermediate-risk disease (Gleason score > or =7, prostate-specific antigen (PSA) > or =10 ng/ml, or clinical stage > or =T2b [1997 American Joint Committee on Cancer]) undergoing brachytherapy with supplemental external beam radiation (XRT). METHODS AND MATERIALS: Seventy-seven consecutive hormone-naïve intermediate-risk prostate cancerpatients received supplemental XRT followed by a brachytherapy boost. No patient underwent pathologic lymph node staging. The median patient age was 69 years and the median follow-up was 52 months. Biochemical disease-free survival was defined by the American Society of Therapeutic Radiology and Oncology consensus definition. Clinical and treatment parameters evaluated included patient age, clinical stage, Gleason score, pretreatment PSA, and isotope. RESULTS: The 6-year actuarial biochemical no-evidence-of-disease survival rate was 97.4%. None of the evaluated clinical or treatment parameters, except for a Gleason score > or =8, predicted for failure. The mean and median posttreatment PSA was 0.08 +/- 0.19 ng/ml and <0.1 ng/ml, respectively. When stratified by isotope, the mean posttreatment PSA was not significantly different (0.07 +/- 0.11 ng/ml for 103Pd vs. 0.14 +/- 0.32 ng/ml for 125I; p=0.397). CONCLUSIONS: Hormone-naïve intermediate-risk prostate cancerpatients undergoing brachytherapy with supplemental XRT have a high probability of 6-year biochemical disease-free survival. None of the evaluated clinical or treatment parameters, except Gleason score > or =8, predicted for treatment failure.
Authors: Michael Dattoli; Kent Wallner; Lawrence True; David Bostwick; Jennifer Cash; Richard Sorace Journal: J Oncol Date: 2010-08-18 Impact factor: 4.375